VRTX Vertex Pharmaceuticals Incorporated

NAS · US · Healthcare · Biotechnology · vrtx.com
523.46USD+0.54%Mkt Cap: 132.01B USDP/E: 33.50

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on spec…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap132.01B USD
Enterprise Value132.18B USD
Revenue (TTM)12.95B USD
Gross Profit10.35B USD
Net Income (TTM)3.95B USD
Revenue/Share51.06 USD
Last Price523.46 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees6.4K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)33.50
P/E (Forward)26.14
PEG2.34
EV/EBITDA25.91
EV/Revenue10.21
P/S10.19
P/B6.31
EPS (TTM)15.54 USD
EPS (Forward)19.92 USD
52W Range
406.6772% of range568.67
52W High568.67 USD
52W Low406.67 USD
Profitability
Gross Margin86.24%
Oper. Margin37.79%
EBITDA Margin39.38%
Profit Margin32.94%
ROE21.18%
ROA15.42%
ROIC27.52%
ROCE20.91%
Growth
Revenue Growth11.80%
Earnings Growth-39.00%
Cash Flow & Leverage
Operating CF3.63B USD
CapEx (TTM)437.60M USD
FCF Margin18.05%
FCF Yield1.77%
Net Debt175.10M USD
Net Debt/EBITDA0.03
Net Debt/FCF0.07
Balance Sheet
Debt/Equity0.11
Current Ratio2.34
Quick Ratio1.72
Book Value/Sh82.47 USD
Cash/Share24.86 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split2:1
Split DateAug 24, 2000
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)595.36 USD
Upside (mean)+13.7%
Target Range350.00 USD – 725.00 USD
350.00+13.7% to mean725.00
# Analysts28
Ownership
Shares Out.253.54M
Float252.79M
Insiders0.27%
Institutions98.34%
Short Interest
Short Ratio3.5d
Short % Float2.14%
Short % Out.1.90%
Shares Short4.81M
Short (prev mo.)4.50M
Technical
SMA 50522.61 (+0.2%)
SMA 200484.35 (+8.1%)
Beta0.28
S&P 52W Chg12.00%
Avg Vol (30d)1.49M
Avg Vol (10d)1.31M
Technical Indicators
RSI (14)43.5
MACD3.3251
MACD Signal6.2166
MACD Hist.-2.8916
BB Upper561.89 USD
BB Middle538.48 USD
BB Lower515.08 USD
BB Width8.69%
ATR (14)15.15 USD
Vol Ratio (20d)0.76x

About Vertex Pharmaceuticals (NASDAQ: VRTX)

›

Vertex Pharmaceuticals (NASDAQ: VRTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 6,400 employees.

The shares were at 523.46 USD on 20 November 2026, up 24.9% over 52 weeks. Its 52-week range is 406.67 USD to 568.67 USD: the price is 8.0% below the high and 28.7% above the low.

At a market capitalisation of 132.01B USD, it trades at 33.5 times trailing earnings and 26.1 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 34.3, so VRTX is valued in line with them.

Vertex Pharmaceuticals reports return on equity of 21.2%, an operating margin of 37.8% and revenue up 11.8% year over year.

Its debt exceeds its cash by 175.10M USD, a debt-to-equity ratio of 0.11. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 28 analysts cover the stock, with an average rating of Buy; their mean price target of 595.36 USD is 13.7% above the current price. The next earnings report is expected on 11 February 2027.